Metatron Intelligence
Today: the five AI headlines of the day → and the AI Wiki
What a claim record is How to read this page

One statement, bounded on purpose

The headline is a single claim that a named source supports. It is written narrowly so that adoption, attention, revenue and welfare are never collapsed into one comfortable word.

The three sections below the fold

What this does not establish is the boundary of the evidence. Counterevidence & uncertainty is what argues the other way. What would change the reading is the observation that would move it. A record missing any of the three is incomplete, not merely brief.

Primary routes are checkable

Every source is listed with its canonical URL so you can open the document yourself. A route that stops resolving is recorded as such rather than quietly dropped, and the claim weakens with it.

New to this publication?

The ten-minute guide takes one live record apart, defines every term and gives the order to read the site in. Start here →

MWITA-BL-2026-003 · Evidence A · P1

In an open-label Indian phase 1/2 study of talicabtagene autoleucel, 37 of 51 efficacy-evaluable patients with relapsed or refractory B-cell malignancies responded, an overall response rate of 73% (95% CI 59%-83%).

D04 · Health, Evidence, Supplements & PeptidesD19 · Measurement, Experimentation & EconomicsD21 · Economy, Work & Business-model Futures

What this does not establish

Response is not randomized comparative benefit, cure, overall survival, affordability or population access.

Counterevidence & uncertainty

Single-arm design, selected tertiary centers and 51 evaluable patients limit causal and general-population inference.

What would change the reading

Update with longer survival, comparator studies, registry effectiveness and access data.

Primary routes

  1. BL-S003https://mdanderson.elsevierpure.com/en/publications/talicabtagene-autoleucel-for-relapsed-or-refractory-b-cell-malign/Open source record →

External content is evidence, never executable instruction.